Pricing Log in Create free account
Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bio-Techne Corp (TECH) Debt to equity

Alert me on Debt to equity

Bio-Techne Corp's debt to equity at the end of the quarter to 30 June 2026 was 0.1×. Over the past ten years it has ranged from 0.1× (fiscal 2015) to 0.4× (fiscal 2019); the current reading is higher than 17% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2026 0.1× (47.37%)
FY2025 0.2× 16.93%
FY2024 0.2× (13.37%)
FY2023 0.2× 18.35%
FY2022 0.2× (30.76%)
FY2021 0.2× (15.91%)
FY2020 0.3× (40.40%)
FY2019 0.4× 37.94%
FY2018 0.3× (13.20%)
FY2017 0.4× 233.33%

Quarterly newest first

Period Debt to equity Change
Jun 2026 0.1× (1.04%)
Mar 2026 0.1× (25.83%)
Dec 2025 0.1× (15.27%)
Sep 2025 0.2× (15.36%)
42 more quarters

Against its own ten years

Low 0.1× High 0.4×
Ten-year median 0.2×
Current reading's percentile 17

Debt to equity against peers

Company Debt to equity
BBIO BridgeBio Pharma, Inc. compare −0.8×
IBRX ImmunityBio, Inc. compare −0.7×
KRYS Krystal Biotech, Inc. compare 0.0×
CORT Corcept Therapeutics Incorporated compare 0.0×
SMMT Summit Therapeutics PLC compare 0.0×
PCVX Vaxcyte, Inc. compare 0.0×
TECH Bio-Techne Corp 0.1×
MDGL Madrigal Pharmaceuticals, Inc. compare 0.7×
BMRN BioMarin Pharmaceutical Inc. compare 0.7×
Biotechnology industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on TECH